However, the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), a prospective randomized controlled trial in patients with T2D and established atherosclerotic CVD, demonstrated a substantial reduction in cardiovascular death and hospitalization for heart failure (HHF) with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i), empagliflozin,13 within a short follow-up period. Here, SLC5A2 is linked to heart failure.